Bruker vs Idexx Laboratories
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Bruker and Idexx Laboratories side by side, using each one’s latest annual report. Here is what stands out:
- Idexx Laboratories is the larger business, with $4.3B of revenue in fiscal 2025 against $3.4B for Bruker.
- Idexx Laboratories grew revenue faster (10.4%, against 2.1%).
- Idexx Laboratories kept more of each dollar of sales as operating profit (31.6% operating margin, against 2.0%).
- Idexx Laboratories turned more of its sales into free cash flow (24.6% FCF margin, against 1.3%).
- Idexx Laboratories earned a higher return on the capital invested in it (57.3%, against 0.9%).
Who comes out ahead
Of the 11 measures where higher (or lower) is clearly better, how many each company leads.
Bruker
BRKR
1/11
5-year growth
Idexx Laboratories
IDXX
10/11
Revenue growthGross marginOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | BRKR FY25 | IDXX FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.9B | $45.2B |
| Revenue | $3.4B | $4.3B |
| Free cash flow | $43.3M | $1.1B |
| Net income | −$8.6M | $1.1B |
| Growth | ||
| Revenue growth | 2.1% | 10.4% |
| 5-year growth | 11.6% | 9.7% |
| Share count change | 1.5% | −2.7% |
| Profitability | ||
| Gross margin | 45.9% | 61.8% |
| Operating margin | 2.0% | 31.6% |
| Net margin | −0.3% | 24.6% |
| FCF margin | 1.3% | 24.6% |
| Return on capital | 0.9% | 57.3% |
| Return on equity | −0.4% | 66.2% |
| Balance sheet | ||
| Net debt | $1.6B | $270M |
| Net debt / EBITDA | 5.5x | 0.2x |
| Dividends and buybacks | $32.8M | $1.2B |
| Valuation & quality | ||
| P/E | — | 40.1x |
| Piotroski F-score | 4 | 8 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.